AES 2024 Breakfast Briefings

This program is supported by an independent medical education grant from Jazz Pharmaceuticals.

Meet the Faculty:

Elaine Wirrell, MD

Professor and Chair
Child and Adolescent Neurology
Mayo Clinic
Rochester MN

Introduction:

Day One:

Abstracts:

A Retrospective Claims Study Evaluating Mortality in Patients with Lennox-gastaut or Dravet Syndromes in the United States

Soticlestat vs Placebo as Adjunctive Therapy for Lennox-gastaut Syndrome: Results from the Phase 3, Randomized SKYWAY Clinical Trial

ENDYMION 2: Phase 3, Open-label Extension Study Assessing Long-term Safety, Tolerability and Secondary Outcomes of Adjunctive Soticlestat in Individuals with Dravet Syndrome or Lennox-gastaut Syndrome

Day Two:

Abstracts:

Clinical Characteristics and Treatment Patterns in Patients with Dravet Syndrome and Lennox-gastaut Syndrome Who Are Prescribed Cannabidiol (CBD)

Onset and Duration of Adverse Events in Patients Treated with Fenfluramine in the Lennox-gastaut Syndrome Clinical Trials

Long-term Experience of VNS in Lennox-gastaut Syndrome at 24 Months from the CORE-VNS Registry

Day Three:

Abstracts:

Prolonged Cardiac Repolarization in Dravet and Lennox-gastaut Syndromes

Pulmonary Complications with Initial Anti-seizure Medications Used for Lennox-gastaut Syndrome

Wrap-up: